Live Breaking News & Updates on Director Kevin Bitterman

Stay updated with breaking news from Director kevin bitterman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Rating of "Moderate Buy" by Brokerages

Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month […] ....

United States , Stifel Nicolaus , Kevin Bitterman , Raymond James , Venture Fund Xlp Atlas , Citigroup Inc , Disc Medicine Inc , Millennium Management , Morgan Stanley , Geode Capital Management , Renaissance Technologies , Cantor Fitzgerald , Disc Medicine , Get Free Report , Marketbeat Ratings , Venture Fund , Director Kevin Bitterman , Capital Management , Point Capital Management , Get Free , Disc Medicine Daily , Nasdaq Iron ,

Disc Medicine's (IRON) Outperform Rating Reiterated at Raymond James

Raymond James reissued their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Monday morning, Marketbeat reports. The brokerage currently has a $40.00 target price on the stock, down from their prior target price of $75.00. A number of other research firms have also recently commented on IRON. […] ....

United States , Kevin Bitterman , Raymond James , Steward Partners Investment Advisory , Cantor Fitzgerald , Morgan Stanley , Securities Exchange Commission , Disc Medicine Inc , Venture Fund Xlp Atlas , America Corp , Ameritas Investment Partners Inc , Disc Medicine , Free Report , Moderate Buy , Get Free Report , Venture Fund , Exchange Commission , Director Kevin Bitterman , Investment Partners , Partners Investment Advisory , Disc Medicine Daily , Nasdaq Iron , Reiterated Rating ,

Disc Medicine's (IRON) Outperform Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report released on Monday morning, RTT News reports. The brokerage currently has a $43.00 target price on the stock, down from their prior target price of $84.00. Wedbush also issued estimates for Disc Medicine’s Q4 2024 earnings at […] ....

United States , Kevin Bitterman , Raymond James , Ameritas Investment Partners Inc , Venture Fund Xlp Atlas , America Corp , Disc Medicine Inc , Cantor Fitzgerald , Steward Partners Investment Advisory , Disc Medicine Company Profile , Securities Exchange Commission , Morgan Stanley , Disc Medicine , Free Report , Moderate Buy , Medicine Trading Down , Get Free Report , Director Kevin Bitterman , Exchange Commission , Venture Fund , Investment Partners , Partners Investment Advisory , Disc Medicine Daily , Nasdaq Iron , Reiterated Rating ,